Journal
TRIALS
Volume 24, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13063-023-07461-3
Keywords
Abdominal aortic aneurysm; High-sensitivity C-reactive protein; Rivaroxaban; Randomized controlled trial; Protocol
Categories
Ask authors/readers for more resources
This study aims to investigate the effect of rivaroxaban on the progression of abdominal aortic aneurysm (AAA) in patients with elevated hs-CRP. Sixty subjects are randomly assigned to the intervention arm (rivaroxaban) or the control arm (aspirin). The primary outcome is the level of serum hs-CRP at 6 months, and secondary outcomes include imaging examination, major adverse cardiovascular and cerebrovascular events, and other laboratory tests.
BackgroundAbdominal aortic aneurysm (AAA) is a fatal disease due to the tendency to rupture. The drug treatment for small AAA without surgical indications has been controversial. Previous studies showed that high-sensitivity C-reactive protein (hs-CRP) had become a potential biomarker of the disease, and the anti-inflammatory effect of rivaroxaban for AAA had been well established. Thus, we hypothesized that rivaroxaban could control the progression of AAA in patients with hs-CRP elevation.MethodsThe study is a prospective, open-label, randomized, controlled clinical trial. Sixty subjects are recruited from the General Hospital of Northern Theatre Command of China. Subjects are randomly assigned (1:1) to the intervention arm (rivaroxaban) or control arm (aspirin). The primary efficacy outcome is the level of serum hs-CRP at 6 months. The secondary outcomes include imaging examination (the maximal diameter of AAA, the maximal thickness of mural thrombus, and the length of aneurysm), major adverse cardiovascular and cerebrovascular events (MACCE, including AAA transformation, non-fatal myocardial infarction, acute congestive heart failure, stent thrombosis, ischemia-driven target vessel revascularization, vascular amputation, stroke, cardiovascular death, and all-cause death), and other laboratory tests (troponin T, interleukin 6, D-dimer, and coagulation function).DiscussionThe BANBOO trial tested the effect of rivaroxaban on the progression of AAA in patients with elevated Hs-CRP for the first time.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available